Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healios KKHLOSF 51 3-Year EBITDA Growth Rate is 38.30% as of Jun. 2026, which is 397% above its 10-year median of 7.70. GuruFocus rates HLOSF with a GF Score™ of 51/100 and a GF Value™ of $0.27. The stock has 6 warning signs investors should review. Among 1,129 Biotechnology companies, Healios KK ranks better than 76.79% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 38.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Healios KK was 38.30% per year. The lowest was -59.90% per year. And the median was 7.70% per year.
Healios KK (OTCPK:HLOSF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Healios KK 3-Year EBITDA Growth Rate Related Terms
HLOSF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Healios KK's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Healios KK's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 38.30% mean?
Healios KK (HLOSF) has a 3-Year EBITDA Growth Rate of 38.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Healios KK and its competitors. This is 397% above median its historical median of 7.70. According to the industry distribution chart, Healios KK ranks #262 out of 1129 companies in the Biotechnology industry, placing it in the top 23.2%.
Is Healios KK's 3-Year EBITDA Growth Rate too high?
Healios KK's current 3-Year EBITDA Growth Rate of 38.30% is 397% above median its 10-year median of 7.70. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Healios KK's value of 38.30% is 160.5% above this industry median. Based on the distribution chart, Healios KK ranks #262 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Healios KK has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Healios KK's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #262 out of 1129 companies for 3-Year EBITDA Growth Rate. This places Healios KK in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Healios KK's value of 38.30% is 160.5% above this benchmark. While the company's 10-year median is 7.70 vs. the industry median of 14.70, Healios KK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healios KK's current 3-Year EBITDA Growth Rate of 38.30% is 160.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Healios KK and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healios KK's current 3-Year EBITDA Growth Rate is 38.30%, which is 397% above median its own 10-year median of 7.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Healios KK (HLOSF) has a current 3-Year EBITDA Growth Rate of 38.30%. The stock's GF Value™ is $0.27, compared to a current price of $1.80 — trading 566.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 38.30%, which is 397% above median its 10-year median of 7.70 and 160.5% above the Biotechnology industry median of 14.70. Healios KK's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Healios KK (HLOSF), the current 3-Year EBITDA Growth Rate is 38.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (HLOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of $1.80 is trading 566.7% above its estimated GF Value™ of $0.27.
Key valuation signals for HLOSF:
3-Year EBITDA Growth Rate: 38.30% (397% above median its 10-year median of 7.70)
GF Value™: $0.27 vs. price of $1.80 (566.7% above fair value)
Industry Position: 160.5% above the Biotechnology median (#262 of 1129)
No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
51GF Score
Get the complete analysis for HLOSF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLOSF has been successfully added to your 
